PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from Brazil and Latin America

Selling into Europe as a biologics and biosimilars maker from Brazil and Latin America

Your team files a European biologics dossier that regulators stop sending back.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Brazil and Latin America, Biologics and biosimilarswho it is written for

Why this training matters

A reviewer at the European Medicines Agency asks where the comparability data behind your biosimilarity claim sits in Module 3, and nobody on the team can point to it. Your answer is late, and the review waits while you search. The launch batch ages in the warehouse and the launch date moves.

What changes after this course

Your regulatory, quality and sales people prepare and defend the dossier themselves, from Module 3 to the reply to the list of questions, without waiting for outside counsel. You hold a certificate per learner and a training record per person for your quality file.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs team stops guessing which comparability data a reviewer at the European Medicines Agency wants. They place each study where Module 3 of the Common Technical Document expects it, and they cite the guideline on similar biological medicinal products when a question arrives. The dossier stops coming back for questions that a clear layout would have prevented.

When the inspector from a European Union authority arrives, your quality director opens records already sorted against EudraLex Volume 4. The importing Qualified Person finds what Annex 16 requires in your site file, so release of a batch in Europe does not wait on a call to Brazil. Nobody scrambles for a missing deviation report.

Safety, legal and export staff each close a gap that used to wait for outside advice. Your pharmacovigilance lead sends serious reactions from Latin America into EudraVigilance under the Qualified Person for Pharmacovigilance. Legal reads a supplementary protection certificate under Regulation (EC) No 469/2009 and names a safe entry date. Export drafts a cold chain protocol that matches the Good Distribution Practice guidelines.

Business development walks into the pricing meeting with a value case built for the market in front of them, whether that is Germany or France. They know how reference pricing can pull a price down, and they plan for it. The whole company then works from one phased entry blueprint that ties Latin American production to European requirements.

Who needs this training

  • Regulatory Affairs Manager for Biosimilars

    Drafts Module 3 and the biosimilarity case, and needs to know which comparability data a European Medicines Agency reviewer accepts before the dossier leaves Brazil.

  • Quality Assurance Director

    A European Union inspector is due at the Brazilian plant, and the director must show the site meets EudraLex Volume 4 with records that are already in order.

  • Export Sales Manager

    A biologics shipment sits in a distributor's warehouse in Europe after a temperature alarm, and the manager must produce the Good Distribution Practice records that decide its fate.

  • Head of Business Development

    Sits across from a payer in France or Germany and must defend the price with a value case that answers what that payer asks.

  • Pharmacovigilance Lead

    A clinic in Mexico or Chile reports a serious reaction, and the lead must get it into EudraVigilance in the form the European rules demand.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: Brazil and Latin America

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Lay out Module 3 of the Common Technical Document so drug substance and drug product data sit where reviewers look for them.
  2. Submit a serious adverse reaction case from Latin America to EudraVigilance through your marketing authorisation holder.
  3. Write a cold chain protocol that matches the European Good Distribution Practice guidelines.
  4. Prepare a pricing and reimbursement file for a payer in Germany or France, with reference pricing in mind.
  5. Check a supplementary protection certificate against your launch plan and record the result in a freedom-to-operate note.
  6. Draft a written reply to a European Medicines Agency list of questions during the formal assessment.
  7. Classify a post-approval change under Regulation (EC) No 1234/2008 before the changed batch ships.

What the company gets

  • Your site meets an inspector with records already matched to EudraLex Volume 4, so the visit tests your plant and not your filing system.
  • The Common Technical Document goes out with Module 3 laid out as reviewers expect, and comparability gaps are closed before submission rather than during the assessment.
  • European distributors can release your biologic shipments sooner because your temperature records answer the questions importers ask.
  • Your pricing and reimbursement case is ready before you sit with a payer, and your team shares one phased entry plan.
  • Each learner holds a certificate and a training record, so your quality file shows who was trained and when.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Map the European Union legal framework that governs your medicinal product

    • Why Regulation (EC) No 726/2004 sends your biologic to the centralised procedure, not to each country.
    • What Directive 2001/83/EC requires of the application, so you can name the article behind each request.
    • Why the marketing authorisation holder must be established in the European Union, and your options.
  2. 2Apply European Medicines Agency guidelines to your biological product

    • The data package that the guideline on similar biological medicinal products expects from you.
    • How to choose the critical quality attributes that your comparability exercise must show.
    • When a product-specific guideline, such as the one for monoclonal antibodies, changes your plan.
  3. 3Build a biosimilarity case that fits the European biosimilar pathway

    • How to set your product beside the reference medicine so a reviewer sees similarity at once.
    • Why a reference product bought outside Europe can require bridging data, and how to plan for it.
    • What to do when the first biosimilarity demonstration shows a gap in a quality attribute.
  4. 4Work with national competent authorities after central approval in the EU

    • What the national competent authorities still decide after the Commission grants your central approval.
    • How to classify a change under Regulation (EC) No 1234/2008 before you ship the first changed batch.
    • Why the sunset clause can end an authorisation for a product that never reaches a pharmacy.
  5. 5Structure Module 3 of the Common Technical Document for a biologic

    • How to lay out Module 3 so the reviewer finds drug substance and drug product data without a query.
    • The cell bank and raw material details that Module 3 must state before the first review.
    • What to show when your process changes between clinical and commercial scale.
  6. 6Pass the European Union Good Manufacturing Practice inspection of your site

    • How to map your Brazilian site against EudraLex Volume 4 and close the gaps before an inspector arrives.
    • The batch and deviation records to have ready on the table when the inspector sits down.
    • Why the importing Qualified Person under Annex 16 needs your site records before releasing a batch.
  7. 7Set up compliant EudraVigilance safety reporting from Brazil

    • How a serious reaction reported in Latin America gets into EudraVigilance, step by step.
    • Why your Qualified Person for Pharmacovigilance must be based in the European Union.
    • What goes into the risk management plan that must accompany your application.
  8. 8Defend price and reimbursement before Health Technology Assessment bodies

    • How the pricing and reimbursement path differs in Germany and France for a biosimilar.
    • Why reference pricing can pull your reimbursed price below your plan, and how to test for it early.
    • What a payer wants to see that the marketing authorisation file does not show.
  9. 9Clear freedom-to-operate checks against European patents and certificates

    • How to read a supplementary protection certificate under Regulation (EC) No 469/2009 for your entry date.
    • The country-by-country patent check that tells you where you can launch and where you must wait.
    • What to do when a patent search finds a claim that touches your cell line or formulation.
  10. 10Prevent cold chain excursions under European Good Distribution Practice

    • How to write a cold chain protocol that matches the European Good Distribution Practice guidelines.
    • Which temperature records a distributor needs to judge a shipment after an excursion.
    • What an importer checks before releasing a quarantined biologic, so your paperwork answers first.
  11. 11Answer European Medicines Agency questions during the assessment

    • How to read the list of questions at day 120 and sort what needs data from what needs an explanation.
    • When to ask for scientific advice from the European Medicines Agency, and when to answer on your own.
    • How to word a response so the reviewer closes the issue and the clock restarts.
  12. 12Finalize a phased market entry blueprint for your first European regions

    • How to rank your first European markets by approval route, price outlook and patent position.
    • What numbers decide between a distributor, a licensing partner and your own commercial office.
    • The checkpoints that tell you when to move the launch to the next region and when to hold.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Brazil and Latin America, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team